Ticking the right boxes

Davis, Tricia Holly
February 2009
Utility Week;2/13/2009, Vol. 30 Issue 7, p2
Trade Publication
The article discusses the energy and utility needs of AstraZeneca, one of the biggest pharmaceutical companies in the world. It is noted that its needs depend on a variety of activities, from research and development of new medicines, to manufacturing and marketing. The company invests in combined heat and power (CHP) at its manufacturing sites.


Related Articles

  • Untitled. Berkin, Chris // EG: Estates Gazette;11/16/2013, Issue 1346, p03 

    The article reports on pharmaceutical company AstraZeneca's investment in a manufacturing facility at Macclesfield in Cheshire, England, to continue the manufacture of injectable cancer treatment drugs.

  • AstraZeneca to invest US$285m in new biologies manufacturing facility in Sweden.  // Checkout;Jun2015, Vol. 41 Issue 6, Special section p10 

    The article discusses the plans of the pharmaceutical company AstraZeneca to invest in a new biological medicines manufacturing facility in Sodertalje, Sweden.

  • AstraZeneca invests £120m in UK production.  // TCE: The Chemical Engineer;Dec2013/Jan2014, Issue 870/871, p12 

    The article reports on the plan of pharmaceutical company AstraZeneca to invest 120 million British pounds in a production site in Macclesfield, England.

  • AstraZeneca Buys Amgen's Biologics Bulk Mfg. Facility.  // Contract Pharma;Oct2015, Vol. 17 Issue 8, p100 

    The article reports on the pharmaceutical company AstraZeneca PLC's procurement of a high-technology biologics bulk manufacturing facility from biotechnology company Amgen, expanding its biologics manufacturing capability in the U.S.

  • South Carolina Welcomes Enhanced Reliability. Bagwell, John // Transmission & Distribution World Exclusive Insight;10/ 1/2014, p15 

    The article focuses on the world's biggest Ibuprofen plant in Orangeburg, South Carolina and its 10-megawatt (MW) power facility. Topics discussed include the power outages that the plant experienced on February 18, 2012 and April 2012 and how the team from the Orangeburg Department of Public...

  • AstraZeneca Opens Plant in China.  // Chemical Market Reporter;5/7/2001, Vol. 259 Issue 19, p14 

    Reports on the opening of a pharmaceutical manufacturing plant by AstraZeneca PLC in Wuxi New District, China in 2001. Drugs manufactured by the pharmaceutical plant; Estimated annual production capacity of the pharmaceutical plant; Comment from an AstraZeneca official about the pharmaceutical...

  • AstraZeneca plans $35m Egyptian pharma build. Gordon, Michael // European Chemical News;11/8/2004, Vol. 81 Issue 2123, p29 

    Reports on the plan of AstraZenica to build a pharmaceutical plant in Cairo, Egypt. Background on the company; Target capacity of tablets per year of the plant in January 2007; Schedule of the plant's construction.

  • AstraZeneca reveals details of 1,600 job cuts.  // TCE: The Chemical Engineer;Apr2013, Issue 862, p8 

    The article reports on the major restructuring of AstraZeneca's research and development operations that will result in 1,600 job cuts and the termination of drug research at its Alderley Park site in Great Britain.

  • In the nick of time.  // MEED: Middle East Economic Digest;4/15/2005, Vol. 49 Issue 15, p39 

    Focuses on the decision of AstraZeneca to open a pharmaceutical manufacturing plant in Egypt. Factors contributing to the rise of investments from pharmaceutical companies in Egypt; Comment from Ahmed Zaghloul, president of marketing at AstraZeneca Egypt, on the company's long-term strategic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics